FDA records linked by MedtechLedger identify Davol, Inc., A Subsidiary of C.R. Bard, Inc. as the applicant behind Phasix ST surgical mesh submissions. The most recent entry in the linked collection is K261543 for Phasix ST Parastomal Hernia Mesh, received May 8, 2026 and decided September 28, 2026 as substantially equivalent under product code OWT, regulation 21 CFR 878.3300, Class II. The same applicant name appears on earlier Phasix ST clearances, giving industry readers a dated view of how the device family has been filed. [1][2][9]
The parastomal filing and its stated device design
K261543 covers Phasix ST Parastomal Hernia Mesh, a Traditional 510(k) with the FDA advisory committee designation General, Plastic Surgery with a Summary statement. The FDA record lists product codes OWT, OOD and FTL and describes the device as P4HB co-kitted with PGA and coated with an absorbable HA/CMC/PEG hydrogel forming the posterior side, with P4HB mesh forming the anterior side, plus a thermoformed channel with hydrogel coating and PGA marker. [1][2]
The same FDA document describes a second configuration built from multiple layers of porcine small intestinal submucosa, a non-crosslinked, decellularized bioabsorbable extracellular collagen matrix held together with biodegradable PGA suture and perforated. These component descriptions are the documented design content of the filing; they are not clinical results. [2]
Earlier Phasix ST clearances
Phasix ST Mesh was cleared under K143380, with the FDA letter dated June 5, 2015 and addressed to C. R. Bard Incorporated at 100 Crossing Boulevard, Warwick, Rhode Island, naming the same regulation and product codes. The notification's bench testing section states that testing compared the proposed device to the TephaFlex Mesh and Ventralight ST Mesh predicates. [8]
K243241, decided February 19, 2025, covers Phasix ST Umbilical Hernia Patch, again under 21 CFR 878.3300, Class II, with product codes OWT, OOD and FTL and the same Warwick address and regulatory contact. Its test tabulation records material chemical characterization by exhaustive extraction and cytotoxicity testing of packaging materials, with pass results reported for the listed methods. [9]
Published manufacturer documentation and study record
BD's product page for Phasix ST Mesh describes a fully bioresorbable scaffold with Sepra technology and lists ordering contacts at 100 Crossings Boulevard, Warwick, Rhode Island. The page's reference list includes a porcine hernia repair characterization study of Poly-4-hydroxybutyrate Phasix Mesh and a paper on bioresorbable mesh reinforcement of crural repair in laparoscopic paraesophageal hernia repair. [7]
A clinical study protocol for Phasix ST, DVL-HE-017, titled ATLAS, is dated April 16, 2018 and names Davol Inc., Subsidiary of C.R. Bard, Inc. as sponsor, describing a post-market, multi-center, prospective, single-arm, open-label study. The protocol document establishes the study design and sponsorship only; no outcomes are reported in the linked material. [6]
What the linked collection does and does not show
The linked collection contains one 510(k) record, K261543, with a substantially equivalent decision, and no recall records. That count is an as-of snapshot of the linked filings, not a measure of total company sales, total portfolio or safety performance. [1]
The applicant name on these filings is Davol, Inc., A Subsidiary of C.R. Bard, Inc.; the relationship to C. R. Bard Incorporated appears in the 2015 clearance letter, and BD publishes the Phasix ST product page. No headquarters, ownership beyond the stated subsidiary relationship, customer list or commercial availability is established by the linked records, and the Warwick addresses are filing addresses. [1][7][8]

